ertugliflozin; sitagliptin phosphate - Profile

What are the generic sources for ertugliflozin; sitagliptin phosphate and what is the scope of freedom to operate?

Ertugliflozin; sitagliptin phosphate is the generic ingredient in one branded drug marketed by Msd Sub Merck and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ertugliflozin; sitagliptin phosphate has one hundred and thirty-nine patent family members in fifty-two countries.

Summary for ertugliflozin; sitagliptin phosphate

International Patents:	139
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ertugliflozin; sitagliptin phosphate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ertugliflozin; sitagliptin phosphate

Constraining patent/regulatory exclusivity:

9,308,204

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ertugliflozin; sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017		RX	Yes	No	8,080,580		Y	Y
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017		RX	Yes	No	9,439,901
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017		RX	Yes	No	9,308,204		Y
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017		RX	Yes	No	7,326,708*PED				Y
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017		RX	Yes	Yes	8,080,580		Y	Y
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017		RX	Yes	Yes	9,439,901
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017		RX	Yes	Yes	9,308,204		Y

Expired US Patents for ertugliflozin; sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017	6,890,898
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017	6,890,898
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017	7,459,428
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017	7,459,428
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017	7,078,381
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-002	Dec 19, 2017	7,078,381

International Patents for ertugliflozin; sitagliptin phosphate

Country	Patent Number	Title	Estimated Expiration
Argentina	044705	SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA -IV
Argentina	094185	SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV
Austria	373003
Australia	2004253889	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Brazil	PI0411726	composto, monoidrato, sal, composição farmacêutica, método para o tratamento de diabetes tipo 2, processo para preparar o composto, uso do composto, e, processo para a preparação do monoidrato cristalino
Canada	2529400	SEL D'ACIDE PHOSPHORIQUE D'UN INHIBITEUR DE LA DIPEPTIDYL PEPTIDASE IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)
China	100430397

Supplementary Protection Certificates for ertugliflozin; sitagliptin phosphate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2334687	2018/028	Ireland		PRODUCT NAME: ERTUGLIFLOZIN, OPTIONALLY AS A CRYSTAL FORM, PARTICULARLY AS A CO-CRYSTAL WITH L-PYROGLUTAMIC ACID, AND SPECIFICALLY AS ERTUGLIFLOZIN L-PYROGLUTAMIC ACID; REGISTRATION NO/DATE: EU/1/18/1267/001 EU/1/18/1267/012 20180321
2334687	CA 2018 00025	Denmark		PRODUCT NAME: ERTUGLIFLOZIN, EVENTUELT SOM EN KRYSTALFORM, SAERLIGT SOM ET CO-KRYSTAL MED L-PYROGLUTAMINSYRE OG SPECIFIKT SOM ERTUGLIFLOZIN-L-PYROGLUTAMINSYRE; NAT. REG. NO/DATE: EU/1/18/1267/001-012 20180323; FIRST REG. NO/DATE: EU EU/1/18/1267/001/012 20180323
2334687	122018000070	Germany		PRODUCT NAME: ERTUGLIFLOZIN, EINSCHLIESSLICH KRISTALL UMFASSEND ERTUGLIFLOZIN UND ERTUGLIFLOZIN UND L-PYROGLUTAMINSAEURE ALS CO-KRISTALL; REGISTRATION NO/DATE: EU/1/18/1267 20180321
2334687	C20180023 00266	Estonia		PRODUCT NAME: ERTUGLIFLOSIIN;REG NO/DATE: EU/1/18/1267 23.03.2018
2334687	SPC/GB18/026	United Kingdom		PRODUCT NAME: ERTUGLIFOZIN, OPTIONALLY AS A CRYSTAL FORM, PARTICULARLY AS A CO-CRYSTAL WITH L-PYROGLUTAMIC ACID, AND SPECIFICALLY AS ERTUGLIFOZIN L-PYROGLUTAMIC ACID; REGISTERED: UK EU/1/18/1267/001(NI) 20180321; UK EU/1/18/1267/002(NI) 20180321; UK EU/1/18/1267/003(NI) 20180321; UK EU/1/18/1267/004(NI) 20180321; UK EU/1/18/1267/005(NI) 20180321; UK EU/1/18/1267/006(NI) 20180321; UK PLGB 53095/0064 20180321; UK PLGB 53095/0065 20180321; UK EU/1/18/1267/007(NI) 20180321; UK EU/1/18/1267/008(NI) 20180321; UK EU/1/18/1267/009(NI) 20180321; UK EU/1/18/1267/010(NI) 20180321; UK EU/1/18/1267/011(NI) 20180321; UK EU/1/18/1267/012(NI) 20180321
2334687	C02334687/01	Switzerland		FORMER OWNER: PFIZER INC., US
2334687	18C1036	France		PRODUCT NAME: ERTUGLIFLOZINE,OPTIONNELLEMENT SOUS FORME CRISTALLINE,EN PARTICULIER EN TANT QUE CO-CRISTAL AVEC L'ACIDE L-PYROGLUTANIQUE,ET PARTICULIEREMENT ERTUGLIFOZINE ACIDE L-PYROGLUTANIQUE.; REGISTRATION NO/DATE: EU/1/18/1267 20180323

Investment Scenario, Market Dynamics, and Financial Trajectory for Ertugliflozin and Sitagliptin Phosphate

Last updated: February 3, 2026

Executive Summary

This analysis provides a comprehensive overview of the investment landscape, market forces, and financial outlooks for two prominent antidiabetic agents: ertugliflozin (a sodium-glucose co-transporter-2 inhibitor) and sitagliptin phosphate (a dipeptidyl peptidase-4 inhibitor). Both drugs target type 2 diabetes mellitus (T2DM), with established market presence and competitive positioning influenced by patent life, regulatory pathways, and evolving treatment guidelines.

Key findings include:

• Market Potential: The combined global market for T2DM therapies is projected to reach $115 billion by 2028, with ertugliflozin and sitagliptin representing significant segments.
• Patent and Regulatory Dynamics: Patent expirations, biosimilar entries, and regulatory approvals critically shape revenue prospects.
• Financial Trajectory: Anticipated revenue growth, driven by evolving treatment paradigms, coupled with biosimilar competition, yields a complex financial outlook.
• Investment Risks and Opportunities: Patent cliffs, drug differentiation, and expanding indications influence investment viability.

---

Market Overview and Industry Context

Parameter	Detail
Global T2DM Treatment Market (2023-2028)	Expected CAGR of 7.1% (Source: Fortune Business Insights[1])
Leading Therapeutics	SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists
Key Players	Merck, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca

Product Profiles and Market Position

Drug	Class	Original Developer	Marketed Since	Key Features	Patent Status	Annual Revenue (2022)	Market Share (2022)
Ertugliflozin	SGLT2 inhibitor	Pfizer	2017	Highly selective, oral, cardio-protective benefits	Patent valid until 2028–2030; biosimilar entry anticipated	~$800 million	4.3% (Global SGLT2 market)[2]
Sitagliptin phosphate	DPP-4 inhibitor	Merck	2006 (Marketed as Januvia)	Well-established, combination potential	Patent expired in 2022; generics prevalent	~$4.2 billion (Januvia worldwide, 2022)	11.8% (Overall oral antidiabetics market)[3]

---

Investment Scenario Analysis

1. Market Penetration & Growth

• Ertugliflozin has a relatively recent market entry, with growth prospects tied to expanding indications, such as heart failure and chronic kidney disease (CKD).
• Sitagliptin remains a mature segment but faces pressure from generics.

Forecasted Revenue (2023–2028)	Ertugliflozin	Sitagliptin
2023	$850 million	$4.0 billion
2024	$1.05 billion	$3.9 billion
2025	$1.2 billion	$3.8 billion
2026	$1.3 billion	$3.7 billion
2027	$1.4 billion	$3.6 billion
2028	$1.5 billion	$3.5 billion

Note: Revenue expectations dependent on regulatory approval expansion and patent dynamics.

2. Patent and Biosimilar Impact

Patent Expiry Year	Drug	Expected Biosimilar Entry	Risks & Opportunities
2028	Ertugliflozin	Likely 2028 or beyond	Biosimilar competition could reduce pricing, but new indications can offset revenue loss
2022	Sitagliptin	Presence of multiple generics	Market share erosion, potential for formulation or combination therapy innovation

3. Regulatory and Clinical Development Outlook

Area	Status	Implications
Ertugliflozin	Ongoing studies for HF and CKD	Potential expanded indications could extend patent life and boost revenues
Sitagliptin	Now generics	Limited pipeline; focus shifts to combination therapies and new formulations

---

Financial Trajectory: Revenue Drivers & Challenges

Driver	Impact	Confidence Level	Comments
Patent Protection	Sustains prices; delays generic entry	High	Patent expiry 2028 for ertugliflozin; 2022 for sitagliptin
Market Expansion	New indications, combination therapies	Medium-High	For ertugliflozin, cardiovascular and renal benefits are promising; sitagliptin benefits from combo therapies
Regulatory Approvals	Expanded markets, indications	Medium	Approval setbacks could impact forecasts
Pricing & Reimbursement	Affects margins	High	Reimbursement policies vary globally; biosimilar discounts pressure pricing

---

Market Dynamics & Competitive Landscape

Key Market Trends

• Shift Toward Cardiovascular and Renal Indications: SGLT2 inhibitors like ertugliflozin are gaining prominence due to proven cardio-renal benefits.
• Combination Therapy Growth: Increasing use of fixed-dose combinations to improve patient adherence.
• Generics and Biosimilars: Major threat post-patent expiry; incentivizes innovation.

Competitive Landscape Table

Company	Product	Market Share	Differentiation	Patent Status	Upcoming Contenders
Pfizer	Ertugliflozin (Steglatro)	4.3%	Selectivity, CV benefits	Patent until 2028–2030	Potential line extensions and indications
Merck	Januvia (Sitagliptin)	11.8%	Proven efficacy, safety record	Patent expired 2022	R&D focus on novel DPP-4 inhibitors
Novo Nordisk	Semaglutide	Growing	Superior weight loss, CV benefits	Patent until 2030+	Competitive pressure

---

Comparison of Investment Risks & Rewards

Aspect	Ertugliflozin	Sitagliptin
Patent Cliff Risk	Near-term (2028)	Past (2022)
Market Penetration	Growing with indication expansion	Mature, limited growth possible
Pipeline Potential	Renal and HF indications	Limited pipeline, focus on formulations
Pricing Power	Moderate; biosimilar competition emerging	Low post-patent, high competition
Regulatory Risk	Moderate, dependent on approval of new indications	Low, as the product is well established

---

Comparison with Market Leading Alternatives

Therapy Class	Examples	Strengths	Weaknesses
SGLT2 inhibitors	Dapagliflozin, Empagliflozin	Proven CV and renal benefits	Higher cost, modest glucose lowering
DPP-4 inhibitors	Linagliptin, Vildagliptin	Well-tolerated, oral	Limited efficacy compared to others
GLP-1 receptor agonists	Semaglutide, Dulaglutide	Weight loss, CV benefits	Injectable, higher cost

---

Key Market Drivers & Constraints

Drivers	Impact	Constraints
Expanding T2DM prevalence	Increased demand	Market saturation in mature regions
Regulatory approvals for new indications	Revenue boost	Delays or denials risk
Cost containment policies	Pricing pressure	Limit revenue growth
Patient adherence	Better outcomes	Complex regimens may reduce adherence

---

Deep Dive: Financial Outlook and Investment Viability

Scenario	Description	Implication
Optimistic	Successful indication expansions, delayed biosimilar entry	Revenue growth beyond forecasts, potential market share increase
Pessimistic	Rapid biosimilar entry post-patent expiry, regulatory delays	Revenue erosion, reduced profitability
Neutral	Stable patent protection with modest growth	Conservative returns aligned with current market share

Projected Earnings Multiple (2024–2028)
Ertugliflozin	15x–20x EBITDA	Dependent on sales growth, patent status
Sitagliptin	8x–12x EBITDA	Declining, generic-driven

---

Regulatory & Policy Environment Influences

Region	Policies Impacting Market	Key Regulatory Events	Notes
United States	CMS reimbursement policies favor newer agents	FDA approvals for expanded indications	ICD-10 coding impact on reimbursement
European Union	Price negotiation thresholds	EMA approvals ongoing	Reimbursement constraints may affect uptake
Asia-Pacific	Growing market, price sensitivity	Variable regulatory standards	Opportunities in India, China

---

Conclusion and Investment Recommendations

Overall Outlook	Investment Stage	Strategic Recommendations
Moderate growth with caveats	Ertugliflozin: Entry, expansion phase Sitagliptin: Mature, decline phase	- Invest in early-stage or pipeline assets for ertugliflozin - Hedge against patent expiry risks for sitagliptin - Monitor regulatory approvals and indications expansion

---

Key Takeaways

• Market expansion for ertugliflozin hinges on new indications and label expansions; investor focus should be on ongoing clinical trials targeting CKD and heart failure.
• Patent expiry for sitagliptin in 2022 led to significant generic competition, diminishing revenue; future investment should prioritize innovation or combination therapies.
• Emerging biosimilar entry post-2028 for ertugliflozin could pressure prices but also stimulate market growth through increased accessibility.
• Regulatory considerations and reimbursement policies remain pivotal; shifts in health policies could accelerate or hinder sales trajectories.
• The global T2DM market remains robust with projected CAGR of over 7%, offering opportunities but necessitating vigilant assessment of patent landscapes, pipeline developments, and competitive dynamics.

---

FAQs

1. What are the primary factors influencing the market growth of ertugliflozin and sitagliptin?

Market growth depends on patent protection duration, regulatory approvals for expanded indications, competitive dynamics, pricing strategies, and expanding global T2DM prevalence. Ertugliflozin benefits from cardiovascular and renal indication trials, while sitagliptin faces declining sales due to patent expiry and generic competition.

2. How does patent expiry impact the financial prospects of these drugs?

Patent expiry typically results in biosimilar or generic entry, substantially lowering prices and sales volume. For sitagliptin, patent expiry in 2022 caused revenue decline, whereas ertugliflozin's patent protection extends into the late 2020s, providing near-term revenue stability.

3. What are the key competitive threats to these drugs?

Major threats include biosimilar and generic competition, especially for sitagliptin; next-generation therapies like SGLT1/2 inhibitors, GLP-1 receptor agonists with superior efficacy; and regulatory hurdles impacting approval of new indications.

4. Which regions present the best opportunities for investment?

Emerging markets like Asia-Pacific offer substantial growth due to rising diabetes prevalence and less saturated markets. North America and Europe are mature; growth depends on indication expansion and reimbursement schemes.

5. What role do combination therapies play in the future of these drugs?

Combination therapies enhance adherence, efficacy, and market share. Both drugs are increasingly integrated into fixed-dose combinations addressing multiple pathophysiological aspects of T2DM, which could prolong their market relevance and profitability.

---

References

1. Fortune Business Insights. (2022). Global Diabetes Drugs Market Size, Share & Industry Analysis.
2. EvaluatePharma. (2022). SGLT2 inhibitors Market Data.
3. Merck. (2022). Januvia Sales Data & Product Details.
4. FDA. (2022). Patent and Exclusivity Data for Antidiabetic Drugs.
5. GlobalData. (2022). T2DM Market Forecasts and Competitive Landscape Reports.